Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017 (2017), Article ID 7304643, 17 pages
https://doi.org/10.1155/2017/7304643
Review Article

(Mesenchymal) Stem Cell-Based Therapy in Cisplatin-Induced Acute Kidney Injury Animal Model: Risk of Immunogenicity and Tumorigenicity

1Department of Nephrology, University Medical Centre Ljubljana, SI-1000 Ljubljana, Slovenia
2Institute of Pathology, Medical Experimental Centre, Faculty of Medicine, University of Ljubljana, Zaloška 4, SI-1105 Ljubljana, Slovenia

Correspondence should be addressed to M. Perše; is.jl-inu.fm@esrep.anitram

Received 25 August 2017; Accepted 12 November 2017; Published 12 December 2017

Academic Editor: Luca Vanella

Copyright © 2017 Ž. Večerić-Haler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. K. Lee, S. H. Lim, I. S. Chung et al., “Preclinical efficacy and mechanisms of mesenchymal stem cells in animal models of autoimmune diseases,” Immune Network, vol. 14, no. 2, pp. 81–88, 2014. View at Publisher · View at Google Scholar
  2. Y. Wang, J. He, X. Pei, and W. Zhao, “Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function in small animal models,” Nephrology, vol. 18, no. 3, pp. 201–208, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Casiraghi, N. Perico, M. Cortinovis, and G. Remuzzi, “Mesenchymal stromal cells in renal transplantation: opportunities and challenges,” Nature Reviews Nephrology, vol. 12, no. 4, pp. 241–253, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Lohan, C. M. Coleman, J. M. Murphy, M. D. Griffin, T. Ritter, and A. E. Ryan, “Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?” Stem Cell Research & Therapy, vol. 5, no. 4, p. 99, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. M. E. Reinders, G. J. Dreyer, J. R. Bank et al., “Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study,” Journal of Translational Medicine, vol. 13, no. 1, p. 344, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Kol, J. A. Wood, D. D. Carrade Holt et al., “Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses,” Stem Cell Research & Therapy, vol. 6, no. 1, p. 73, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Wang, H. Jia, B. Zhang et al., “Pre-incubation with hucMSC-exosomes prevents cisplatin-induced nephrotoxicity by activating autophagy,” Stem Cell Research & Therapy, vol. 8, no. 1, p. 75, 2017. View at Publisher · View at Google Scholar
  8. J. H. Park, H. R. Jang, D. H. Kim et al., “Early, but not late treatment with human umbilical cord blood-derived mesenchymal stem cells attenuates cisplatin nephrotoxicity through immunomodulation,” American Journal of Physiology Renal Physiology, vol. 313, no. 4, pp. F984–F996, 2017. View at Publisher · View at Google Scholar
  9. R. H. Ashour, M. A. Saad, M. A. Sobh et al., “Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats,” Stem Cell Research & Therapy, vol. 7, no. 1, p. 126, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Yao, Q. Hu, Y. Ma et al., “Human adipose-derived mesenchymal stem cells repair cisplatin-induced acute kidney injury through antiapoptotic pathways,” Experimental and Therapeutic Medicine, vol. 10, no. 2, pp. 468–476, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. S. R. Burks, B. A. Nguyen, P. A. Tebebi et al., “Pulsed focused ultrasound pretreatment improves mesenchymal stromal cell efficacy in preventing and rescuing established acute kidney injury in mice,” Stem Cells, vol. 33, no. 4, pp. 1241–1253, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. R. H. Shalaby, L. A. Rashed, A. E. Ismaail, N. K. Madkour, and S. H. Elwakeel, “Hematopoietic stem cells derived from human umbilical cord ameliorate cisplatin-induced acute renal failure in rats,” American Journal of Stem Cells, vol. 3, no. 2, pp. 83–96, 2014. View at Google Scholar
  13. X. Peng, H. Xu, Y. Zhou et al., “Human umbilical cord mesenchymal stem cells attenuate cisplatin-induced acute and chronic renal injury,” Experimental Biology and Medicine, vol. 238, no. 8, pp. 960–970, 2013. View at Publisher · View at Google Scholar
  14. J. Luo, X. Zhao, Z. Tan, Z. Su, F. Meng, and M. Zhang, “Mesenchymal-like progenitors derived from human embryonic stem cells promote recovery from acute kidney injury via paracrine actions,” Cytotherapy, vol. 15, no. 6, pp. 649–662, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. H. Kim, D. J. Park, J. C. Yun et al., “Human adipose tissue-derived mesenchymal stem cells protect kidneys from cisplatin nephrotoxicity in rats,” American Journal of Physiology Renal Physiology, vol. 302, no. 9, pp. F1141–F1150, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Bi, R. Schmitt, M. Israilova, H. Nishio, and L. G. Cantley, “Stromal cells protect against acute tubular injury via an endocrine effect,” Journal of the American Society of Nephrology, vol. 18, no. 9, pp. 2486–2496, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Gheisari, N. Ahmadbeigi, M. Naderi, S. M. Nassiri, S. Nadri, and M. Soleimani, “Stem cell-conditioned medium does not protect against kidney failure,” Cell Biology International, vol. 35, no. 3, pp. 209–213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Santeramo, Z. Herrera Perez, A. Illera et al., “Human kidney-derived cells ameliorate acute kidney injury without engrafting into renal tissue,” Stem Cells Translational Medicine, vol. 6, no. 5, pp. 1373–1384, 2017. View at Publisher · View at Google Scholar
  19. W. W. Wang, Z. Z. Li, W. Wang et al., “Enhanced renoprotective effect of HIF-1α modified human adipose-derived stem cells on cisplatin-induced acute kidney injury in vivo,” Scientific Reports, vol. 5, no. 1, article 10851, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Papadimou, M. Morigi, P. Iatropoulos et al., “Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts,” Stem Cell Reports, vol. 4, no. 4, pp. 685–698, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Imberti, S. Tomasoni, O. Ciampi et al., “Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury,” Scientific Reports, vol. 5, no. 1, p. 8826, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Gheisari, N. Ahmadbeigi, S. H. Aghaee-Bakhtiari et al., “Human unrestricted somatic stem cell administration fails to protect nude mice from cisplatin-induced acute kidney injury,” Nephron Experimental Nephrology, vol. 123, no. 3-4, pp. 11–21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Yuan, M. J. Wu, H. Y. Sun et al., “VEGF-modified human embryonic mesenchymal stem cell implantation enhances protection against cisplatin-induced acute kidney injury,” American Journal of Physiology Renal Physiology, vol. 300, no. 1, pp. F207–F218, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Eliopoulos, J. Zhao, M. Bouchentouf et al., “Human marrow-derived mesenchymal stromal cells decrease cisplatin renotoxicity in vitro and in vivo and enhance survival of mice post-intraperitoneal injection,” American Journal of Physiology Renal Physiology, vol. 299, no. 6, pp. F1288–F1298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Morigi, C. Rota, T. Montemurro et al., “Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury,” Stem Cells, vol. 28, no. 3, pp. 513–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. H. Roudkenar, R. Halabian, H. A. Tehrani et al., “Lipocalin 2 enhances mesenchymal stem cell-based cell therapy in acute kidney injury rat model,” Cytotechnology, 2017. View at Publisher · View at Google Scholar
  28. Y. Zhu, J. Yu, L. Yin et al., “MicroRNA-146b, a sensitive indicator of mesenchymal stem cell repair of acute renal injury,” Stem Cells Translational Medicine, vol. 5, no. 10, pp. 1406–1415, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. F. E. Moustafa, M. A. Sobh, M. Abouelkheir, Y. Khater, K. Mahmoud, and M. A. Saad, “Study of the effect of route of administration of mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague Dawley rats,” International Journal of Stem Cells, vol. 9, no. 1, pp. 79–89, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. Overath, S. Gauer, N. Obermüller et al., “Short-term preconditioning enhances the therapeutic potential of adipose-derived stromal/stem cell-conditioned medium in cisplatin-induced acute kidney injury,” Experimental Cell Research, vol. 342, no. 2, pp. 175–183, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Bataille, P. Galichon, M. Wetzstein et al., “Evaluation of the ability of bone marrow derived cells to engraft the kidney and promote renal tubular regeneration in mice following exposure to cisplatin,” Renal Failure, vol. 38, no. 4, pp. 521–529, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Mohammadzadeh-Vardin, M. Habibi Roudkenar, and A. Jahanian-Najafabadi, “Adenovirus-mediated over-expression of Nrf2 within mesenchymal stem cells (MSCs) protected rats against acute kidney injury,” Advanced Pharmaceutical Bulletin, vol. 5, no. 2, pp. 201–208, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. A. K. Gupta, S. H. Jadhav, N. K. Tripathy, and S. Nityanand, “Fetal kidney stem cells ameliorate cisplatin induced acute renal failure and promote renal angiogenesis,” World Journal of Stem Cells, vol. 7, no. 4, pp. 776–788, 2015. View at Publisher · View at Google Scholar
  34. I. O. Sherif, L. A. Al-Mutabagani, A. M. Alnakhli, M. A. Sobh, and H. E. Mohammed, “Renoprotective effects of angiotensin receptor blocker and stem cells in acute kidney injury: involvement of inflammatory and apoptotic markers,” Experimental Biology and Medicine, vol. 240, no. 12, pp. 1572–1579, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Qi and D. Wu, “Bone marrow-derived mesenchymal stem cells protect against cisplatin-induced acute kidney injury in rats by inhibiting cell apoptosis,” International Journal of Molecular Medicine, vol. 32, no. 6, pp. 1262–1272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Cheng, P. Rai, A. Plagov et al., “Transplantation of bone marrow-derived MSCs improves cisplatinum-induced renal injury through paracrine mechanisms,” Experimental and Molecular Pathology, vol. 94, no. 3, pp. 466–473, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Yasuda, T. Ozaki, Y. Saka et al., “Autologous cell therapy for cisplatin-induced acute kidney injury by using non-expanded adipose tissue-derived cells,” Cytotherapy, vol. 14, no. 9, pp. 1089–1100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Eliopoulos, J. Zhao, K. Forner, E. Birman, Y. K. Young, and M. Bouchentouf, “Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice,” Molecular Therapy, vol. 19, no. 11, pp. 2072–2083, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Zarjou, J. Kim, A. M. Traylor et al., “Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1,” American Journal of Physiology Renal Physiology, vol. 300, no. 1, pp. F254–F262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Y. Lim, J. I. Han, S. G. Kim, C. M. Lee, and H. M. Park, “Evaluation of autologous bone marrow–derived mesenchymal stem cells on renal regeneration after experimentally induced acute kidney injury in dogs,” American Journal of Veterinary Research, vol. 77, no. 2, pp. 208–217, 2016. View at Publisher · View at Google Scholar
  41. R. Moghadasali, M. Hajinasrollah, H. Argani et al., “Autologous transplantation of mesenchymal stromal cells tends to prevent progress of interstitial fibrosis in a rhesus Macaca mulatta monkey model of chronic kidney disease,” Cytotherapy, vol. 17, no. 11, pp. 1495–1505, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Moghadasali, M. Azarnia, M. Hajinasrollah et al., “Intra-renal arterial injection of autologous bone marrow mesenchymal stromal cells ameliorates cisplatin-induced acute kidney injury in a rhesus Macaque mulatta monkey model,” Cytotherapy, vol. 16, no. 6, pp. 734–749, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Wagner, B. Kreft, G. Bohlmann, and G. Schwieder, “Effects of fosfomycin, mesna, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin,” Journal of Cancer Research and Clinical Oncology, vol. 114, no. 5, pp. 497–501, 1988. View at Publisher · View at Google Scholar · View at Scopus
  44. F. A. Levi, W. J. Hrushesky, F. Halberg, T. R. Langevin, E. Haus, and B. J. Kennedy, “Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration,” European Journal of Cancer & Clinical Oncology, vol. 18, no. 5, pp. 471–477, 1982. View at Publisher · View at Google Scholar · View at Scopus
  45. W. J. Hrushesky, F. A. Levi, F. Halberg, and B. J. Kennedy, “Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats,” Cancer Research, vol. 42, no. 3, pp. 945–949, 1982. View at Google Scholar
  46. G. S. Baldew, C. J. van den Hamer, G. Los, N. P. Vermeulen, J. J. de Goeij, and J. G. McVie, “Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats,” Cancer Research, vol. 49, no. 11, pp. 3020–3023, 1989. View at Google Scholar
  47. G. S. Baldew, J. G. McVie, M. A. van der Valk, G. Los, J. J. de Goeij, and N. P. Vermeulen, “Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen,” Cancer Research, vol. 50, no. 21, pp. 7031–7036, 1990. View at Google Scholar
  48. T. Nakamura, A. Yonezawa, S. Hashimoto, T. Katsura, and K. Inui, “Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity,” Biochemical Pharmacology, vol. 80, no. 11, pp. 1762–1767, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. D. L. Bodenner, P. C. Dedon, P. C. Keng, J. C. Katz, and R. F. Borch, “Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate,” Cancer Research, vol. 46, no. 6, pp. 2751–2755, 1986. View at Google Scholar
  50. H. Kawai, W. Sato, Y. Yuzawa et al., “Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage,” The American Journal of Pathology, vol. 165, no. 5, pp. 1603–1612, 2004. View at Publisher · View at Google Scholar
  51. S. G. Allan, J. F. Smyth, F. G. Hay, R. C. Leonard, and C. R. Wolf, “Protective effect of sodium-2-mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of cis-diamminedichloroplatinum,” Cancer Research, vol. 46, no. 7, pp. 3569–3573, 1986. View at Google Scholar
  52. G. W. Hill, D. K. Morest, and K. Parham, “Cisplatin-Induced Ototoxicity,” Otology & Neurotology, vol. 29, no. 7, pp. 1005–1011, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Parham, “Can intratympanic dexamethasone protect against cisplatin ototoxicity in mice with age-related hearing loss?” Otolaryngology and Head and Neck Surgery, vol. 145, no. 4, pp. 635–640, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Naganuma, M. Satoh, and N. Imura, “Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice,” Cancer Research, vol. 47, no. 4, pp. 983–987, 1987. View at Google Scholar
  55. A. A. Al-Majed, M. M. Sayed-Ahmed, A. A. Al-Yahya, A. M. Aleisa, S. S. Al-Rejaie, and O. A. Al-Shabanah, “Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model,” Pharmacological Research, vol. 53, no. 3, pp. 278–286, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. W. R. Leopold, E. C. Miller, and J. A. Miller, “Carcinogenicity of antitumor cis-platinum(II) coordination complexes in the mouse and rat,” Cancer Research, vol. 39, no. 3, pp. 913–918, 1979. View at Google Scholar
  57. K. Le Blanc, C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringdén, “HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells,” Experimental Hematology, vol. 31, no. 10, pp. 890–896, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. K. H. Grinnemo, M. Kumagai-Braesch, A. Månsson-Broberg et al., “Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings,” Reproductive Biomedicine Online, vol. 13, no. 5, pp. 712–724, 2006. View at Publisher · View at Google Scholar
  59. A. J. Poncelet, J. Vercruysse, A. Saliez, and P. Gianello, “Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo,” Transplantation, vol. 83, no. 6, pp. 783–790, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Du and Y. J. Zhu, “The regulation of inflammatory mediators in acute kidney injury via exogenous mesenchymal stem cells,” Mediators of Inflammation, vol. 2014, Article ID 261697, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. C. S. Lin, G. Lin, and T. F. Lue, “Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants,” Stem Cells and Development, vol. 21, no. 15, pp. 2770–2778, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. K. H. Grinnemo, A. Månsson, G. Dellgren et al., “Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium,” The Journal of Thoracic and Cardiovascular Surgery, vol. 127, no. 5, pp. 1293–1300, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. K. H. Grinnemo, A. Månsson-Broberg, K. Leblanc et al., “Human mesenchymal stem cells do not differentiate into cardiomyocytes in a cardiac ischemic xenomodel,” Annals of Medicine, vol. 38, no. 2, pp. 144–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. X. P. Huang, Z. Sun, Y. Miyagi et al., “Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair,” Circulation, vol. 122, no. 23, pp. 2419–2429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. A. J. Nauta, G. Westerhuis, A. B. Kruisselbrink, E. G. Lurvink, R. Willemze, and W. E. Fibbe, “Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting,” Blood, vol. 108, no. 6, pp. 2114–2120, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Inoue, F. C. Popp, G. E. Koehl et al., “Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model,” Transplantation, vol. 81, no. 11, pp. 1589–1595, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. Z. Zdrojewicz, E. Pachura, and P. Pachura, “The thymus: a forgotten, but very important organ,” Advances in Clinical and Experimental Medicine, vol. 25, no. 2, pp. 369–375, 2016. View at Publisher · View at Google Scholar · View at Scopus
  68. G. Liu, L. Wang, T. Pang et al., “Umbilical cord-derived mesenchymal stem cells regulate thymic epithelial cell development and function in Foxn1 / mice,” Cellular & Molecular Immunology, vol. 11, no. 3, pp. 275–284, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. L. Kilpinen, U. Impola, L. Sankkila et al., “Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning,” Journal of Extracellular Vesicles, vol. 2, no. 1, 2013. View at Publisher · View at Google Scholar
  70. A. Technau, K. Froelich, R. Hagen, and N. Kleinsasser, “Adipose tissue-derived stem cells show both immunogenic and immunosuppressive properties after chondrogenic differentiation,” Cytotherapy, vol. 13, no. 3, pp. 310–317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Chinnadurai, M. A. Garcia, Y. Sakurai et al., “Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo,” Stem Cell Reports, vol. 3, no. 1, pp. 60–72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Barkholt, E. Flory, V. Jekerle et al., “Risk of tumorigenicity in mesenchymal stromal cell–based therapies—bridging scientific observations and regulatory viewpoints,” Cytotherapy, vol. 15, no. 7, pp. 753–759, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. F. Casiraghi, G. Remuzzi, M. Abbate, and N. Perico, “Multipotent mesenchymal stromal cell therapy and risk of malignancies,” Stem Cell Reviews, vol. 9, no. 1, pp. 65–79, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Houghton, C. Stoicov, S. Nomura et al., “Gastric cancer originating from bone marrow-derived cells,” Science, vol. 306, no. 5701, pp. 1568–1571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. A. B. Mohseny, K. Szuhai, S. Romeo et al., “Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2,” The Journal of Pathology, vol. 219, no. 3, pp. 294–305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. A. L. Berkowitz, M. B. Miller, S. A. Mir et al., “Glioproliferative lesion of the spinal cord as a complication of “stem-cell tourism”,” The New England Journal of Medicine, vol. 375, no. 2, pp. 196–198, 2016. View at Publisher · View at Google Scholar · View at Scopus
  77. D. Thirabanjasak, K. Tantiwongse, and P. S. Thorner, “Angiomyeloproliferative lesions following autologous stem cell therapy,” Journal of the American Society of Nephrology, vol. 21, no. 7, pp. 1218–1222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. L. B. Travis, R. E. Curtis, H. Storm et al., “Risk of second malignant neoplasms among long-term survivors of testicular cancer,” Journal of the National Cancer Institute, vol. 89, no. 19, pp. 1429–1439, 1997. View at Publisher · View at Google Scholar
  79. G. N. Wogan, S. S. Hecht, J. S. Felton, A. H. Conney, and L. A. Loeb, “Environmental and chemical carcinogenesis,” Seminars in Cancer Biology, vol. 14, no. 6, pp. 473–486, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. Ž. Večerić-Haler, A. Erman, A. Cerar et al., “Improved protective effect of umbilical cord stem cell transplantation on cisplatin-induced kidney injury in mice pretreated with antithymocyte globulin,” Stem Cells International, vol. 2016, Article ID 3585362, 12 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Katariya and R. J. Thurer, “Malignancies associated with the immunocompromised state,” Chest Surgery Clinics of North America, vol. 9, pp. 63–77, 1999. View at Google Scholar
  82. R. J. Prestwich, F. Errington, P. Hatfield et al., “The immune system is it relevant to cancer development, progression and treatment?” Clinical Oncology, vol. 20, no. 2, pp. 101–112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. T. E. Robey, M. K. Saiget, H. Reinecke, and C. E. Murry, “Systems approaches to preventing transplanted cell death in cardiac repair,” Journal of Molecular and Cellular Cardiology, vol. 45, no. 4, pp. 567–581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Lee, E. Choi, M. J. Cha, and K. C. Hwang, “Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 632902, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Idziak, P. Pędzisz, A. Burdzińska, K. Gala, and L. Pączek, “Uremic toxins impair human bone marrow-derived mesenchymal stem cells functionality in vitro,” Experimental and Toxicologic Pathology, vol. 66, no. 4, pp. 187–194, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. C. Kilkenny, W. J. Browne, I. C. Cuthill, M. Emerson, and D. G. Altman, “Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research,” PLoS Biology, vol. 8, no. 6, article e1000412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. C. R. Hooijmans, M. Leenaars, and M. Ritskes-Hoitinga, “A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible,” Alternatives to Laboratory Animals, vol. 38, no. 2, pp. 167–182, 2010. View at Google Scholar